EGFR+ Non–Small Cell Lung Cancer: Frontline Options

Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon EGFR MutationsПодробнее

First line treatment options for activating EGFR non-small cell lung Cancer | Dr. Alexander SpiraПодробнее

Novel frontline approaches to treating patients with EGFR-mutated NSCLCПодробнее

Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLCПодробнее

Lung Cancer BCOP 2021 Study ReviewПодробнее

ILCN Multidisciplinary Forum: Understanding Treatment Options and Resistance in EGFR-positive NSCLCПодробнее

Immunotherapy in Non-Small Cell Lung Cancer (NSCLC): Front Line TherapyПодробнее

Lung cancer molecular testingПодробнее

Treatment Options: Newly Diagnosed EGFR+ NSCLCПодробнее

Phase III Data Support Frontline Osimertinib in EGFR-Mutant Lung CancersПодробнее

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positi...Подробнее

Dr. Clarke on Available EGFR TKIs in Frontline Treatment of EGFR+ NSCLCПодробнее

Case 2: Frontline Therapy in EGFR-Mutated Lung CancerПодробнее

Frontline Treatment for EGFR+ NSCLCПодробнее

Examining Data for Osimertinib in EGFR+ Lung CancerПодробнее

Osimertinib for Treatment of EGFR+ Lung CancerПодробнее

Understanding, preventing, and delaying EGFR resistance in the era of OsimertinibПодробнее

Targeted treatment with EGFR TKIs: Front line optionsПодробнее

Systemic Therapy Options for Non–Small Cell Lung CancerПодробнее

Osimertinib as Frontline Therapy for EGFR-Positive NSCLCПодробнее